Holen Sie sich die Stockscreener-App
1.485
1.32%
-0.025
Schlusskurs vom Vortag:
$1.51
Offen:
$1.52
24-Stunden-Volumen:
60,906
Relative Volume:
0.05
Marktkapitalisierung:
$102.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-89.66M
KGV:
-0.6135
EPS:
-2.4205
Netto-Cashflow:
$-81.90M
1W Leistung:
+7.97%
1M Leistung:
-3.25%
6M Leistung:
-75.53%
1J Leistung:
+2.05%
1-Tages-Spanne:
$1.4706
$1.56
1-Wochen-Bereich:
$1.37
$1.595
52-Wochen-Spanne:
$1.01
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Firmenname
Pepgen Inc
Sektor
Branche
Telefon
703-456-8000
Adresse
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.48 | 104.45M | 0 | -89.66M | -81.90M | -2.4205 |
VRTX
Vertex Pharmaceuticals Inc
|
435.24 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
640.33 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.47 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.11 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.77 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-09 | Eingeleitet | Guggenheim | Buy |
| 2024-12-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-07-31 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-21 | Eingeleitet | H.C. Wainwright | Buy |
Pepgen Inc Aktie (PEPG) Neueste Nachrichten
[EFFECT] PepGen Inc. SEC Filing - Stock Titan
PEPG Stock Price, Quote & Chart | PEPGEN INC (NASDAQ:PEPG) - ChartMill
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program - BioSpace
PepGen’s PGN-EDODM1 Shows Promising Safety and Efficacy in Myotonic Dystrophy Type 1 Clinical Trials – FREEDOM2 Study Update - Minichart
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting - PharmiWeb.com
PepGen unveils new PGN-EDODM1 clinical data at IDMC-15 - Traders Union
PepGen Highlights DM1 Program Progress in Updated Presentation - TipRanks
H.C. Wainwright reiterates PepGen stock rating on data outlook - Investing.com
PepGen updates corporate presentation, highlights FREEDOM2 milestones and PGN-EDODM1 data - TradingView
PepGen (NASDAQ: PEPG) details DM1 trial data and cash runway outlook - Stock Titan
H.C. Wainwright reiterates PepGen stock rating on data outlook By Investing.com - Investing.com Canada
PepGen (PEPG) loses 14.3% in 4 weeks, here's why a trend reversal may be around the corner - MSN
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance Singapore
PepGen files to offer up to $400 mln in securities from time to time - marketscreener.com
PepGen Files To Offer Up To $400 Mln In Securities From Time To Time - TradingView
According to documents submitted to the SEC, biotechnology company PepGen Inc. has signed a new sales agreement, which will completely replace the company's previous sales arrangement. - Bitget
PepGen (NASDAQ: PEPG) ups capital flexibility with $400M shelf and $100M ATM - Stock Titan
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now? - Insider Monkey
Why is PepGen stock sinking Tuesday? - MSN
PepGen (PEPG) upgraded to buy: Here's what you should know - MSN
Viking Global reports 3.48M shares in PepGen (NASDAQ: PEPG) - Stock Titan
[SCHEDULE 13G/A] PepGen Inc. Amended Passive Investment Disclosure - Stock Titan
TradingKey - TradingKey
Wedbush Maintains PepGen(PEPG.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
PepGen Inc. Stock 12‑Month Price Target Cut to $10, Implies 495% Upside - TradingView
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Wedbush Trims Price Target on PepGen to $4 From $5, Maintains Outperform Rating - marketscreener.com
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - BioSpace
PepGen: $132.3M of Cash as of March 31 Sufficient to Fund Ops Through FREEDOM2 12.5 Mg/kg MAD Readout and Into 2H 2027 >PEPG - Moomoo
First quarter 2026 financial results released as PepGen announces new corporate developments - Traders Union
PepGen Q1 loss narrows as operating expenses fall - TradingView
PepGen (PEPG) posts Q1 2026 loss, updates FREEDOM2-DM1 trial and FDA hold - Stock Titan
PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
PepGen (NASDAQ: PEPG) cuts Q1 2026 loss as cash reaches $132.3M - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - ACCESS Newswire
MSN Money - MSN
PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PepGen Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Pictet Asset Management Holding SA Purchases 871,059 Shares of PepGen, Inc. $PEPG - MarketBeat
PepGen falls 20% despite earnings beat on FDA hold concerns By Investing.com - Investing.com Nigeria
PepGen crashes after mid-stage trial data for muscle disorder therapy - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - FinancialContent
[ARS] PepGen Inc. SEC Filing - Stock Titan
PepGen (NASDAQ: PEPG) details 2026 virtual meeting and auditor vote - Stock Titan
PepGen advances momentum with Palo Alto meeting on DM1 community engagement - Traders Union
PepGen shares slide 20% as FDA clinical hold overshadows earnings beat - MSN
Wedbush Maintains PepGen (PEPG) Outperform Recommendation - MSN
Finanzdaten der Pepgen Inc-Aktie (PEPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):